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The relationship between the functional capacity of T  cell subsets and the differ- 
entiation antigens on their cell surfaces has been the subject of many recent studies in 
mice and humans. Swain and colleagues (1-3) provided evidence that murine T  cells 
that respond to class I  (H-2K and H-2D) major histocompatibility complex (MHC) a 
antigens express high levels of Lyt-2 antigen. This was observed not only for cytotoxic 
T  lymphocytes (CTL) but also for T  cells that produce nonspecific helper factors for 
antibody  production  as  well  as  T  cell  growth  factor  (TCGF)  (1-3).  Anti-Lyt-2 
antibody could block the cytotoxic function  as well as the helper cell function  and 
TCGF release of class I-reactive alloimmune T  cells (3).  Thus, the Lyt-2 molecule is 
not  only  expressed  on  the  cell  surface  but  also  may  play  some  role  in  antigen 
recognition by T  cells because it has been observed that anti-Lyt-2 antibodies interfere 
with the functions of class I-specific T  cells (3-10). 
In contrast,  T  cells  that  respond  to class  II antigens  (H-2I-encoded Ia antigens) 
were shown  to be Lyt-2-, regardless of their  functions,  and could not  be inhibited 
with anti-Lyt-2 antibodies  (2, 3).  These results have led to the conclusion that most, 
if not all, class I-reactive T  cells are Lyt-2  +, and class II-reactive T  cells are Lyt-2-. 
Some of these observations in  murine systems have been paralleled  by results of 
human studies. Monoclonal antibodies have been developed that detect a differentia- 
tion  antigen  (designated  OKT8  or  Leu-2)  (11-13)  that  is  present  on  CTL  and 
suppressor-effector cells but is generally absent  from cells with helper/inducer  func- 
tions (14). Like the murine anti-Lyt-2 antibodies, antibodies to the OKT8 molecules 
have been shown to inhibit allogeneic cytotoxic activity (12,  15,  16)  and CTL-target 
cell conjugate formation (16). We tested and verified the hypothesis that this antibody, 
like murine anti-Lyt-2, is present on (and interferes with the function of) those CTL 
that  react  with human  class I  antigens  but  not  those  CTL that  react with  human 
* To whom correspondence should be addressed at Building 36, Room 5D-14, National Institutes of 
Health, Bethesda, MD 20205. 
1Abbreviations used in  this paper."  CTL,  cytotoxie T  lymphocytes; MHC,  major histocompatibility 
complex; MLC, mixed lymphocyte culture; PBL, peripheral blood lymphocytes; PHA, phytohemaggluti- 
nin; TCGF, T cell growth factor. 
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class II antigens. 
Additional monoclonal antibodies define a  human T  cell differentiation marker 
(designated OKT4 or Leu 3)  (11-13) that is generally found on helper/inducer cells; 
these cells might be the counterpart of the  murine Lyt-2- cells. The availability of 
these reagents made it possible to test the hypothesis that the OKT4 antigen on class 
II-specific CTL is analogous to  the OKT8  antigen on class I-specific CTL.  Recent 
findings in several laboratories suggest that OKT4 may mark CTL that are specific 
for HLA-DR antigens (17,  18),  the best characterized human class II gene products. 
We  found evidence to  support  this hypothesis using CTL directed  at  SB  antigens. 
These recently discovered HLA antigens are similar to HLA-DR antigens in structure 
and tissue distribution (19-22);  however,  the SB  gene is distinguishable genetically 
from  HLA-DR  (20-22), and its gene product can be separated  immunochemically 
from HLA-DR (22-23). Based on the ability of a  series of monoclonal antibodies to 
the OKT4 molecule to inhibit SB-specific killing, a  model is proposed for the role of 
the OKT4 molecule in interactions between T  cells and Ia-positive cells. 
Materials and Methods 
Human Blood Reagents.  Peripheral blood mononuclear leukocytes (PBL)  and plasma were 
obtained by batch leukapheresis of normal adult volunteers and were separated by flotation on 
Ficoll-Hypaque as described (24). Plasma from 5  10 such male donors was pooled, frozen in 
aliquots at -20°C, and used as the normal human plasma pool. Fresh PBL were cryopreserved 
and thawed as previously described (24). HLA-serotyping of cells was kindly performed by Dr. 
R.J. Duquesnoy, Blood Center of Southeastern Wisconsin, Milwaukee, WI. 
Immunochemical Reagents.  Purified  monoclonal antibodies were  prepared  from  ascites  as 
previously described (11). The monoclonal antibodies used in these studies are OKT1  (IgG1) 
(25),  OKT3  (Ige2a)  (11),  OKT4  (IgG2b)  (ll), OKT4A (Ig61)  (26),  OKT4B  (IgM)  (26), 
OKT4C (IgG1)  (26), OKT4D (IgG3)  (26), OKT8A (IgG2)  (27), and OKT9 (IgG1)  (28). 
Generation and Assay of CTL.  Cytotoxic  effector  cells  were  generated  in  one-way mixed 
lymphocyte culture (MLC) of cells from donors carefully selected  to have limited disparity of 
their HLA histocompatibility antigens. For the SB-specific effectors,  the donors were matched 
for HLA-A, -B, -C, -D, -DR, MB, and MT, but mismatched for SB; donor combinations were 
identical to those used to generate the standard primed lymphocyte typing reagents that define 
the SB specificities  (19, 29). The details of culture were as previously described (29). For the 
HLA-A2-specific effectors,  matching was for all HLA-A and -B antigens other than HLA-A2. 
HLA-A2-specific CTL were  used  after  primary or secondary stimulation, whereas  the  SB- 
specific  CTL were  used after secondary or tertiary stimulation. Restimulation in a  tertiary 
response  (to amplify cell yield) was  performed in a  manner analogous to that  described for 
secondary restimulation. 
The 51Cr release cytotoxicity assay was performed as previously described (19). Effector cells 
were assayed at four or more effector-to-target cell ratios.  Results are expressed  as mean percent 
specific  lysis (19). Standard errors  for  percent lysis were <5%  and are omitted for clarity of 
presentation. Lytic unit calculations were performed as previously described (23). Target cells 
were either lymphoblasts prepared by 3-d stimulation of PBL with phytohemagglutinin (PHA 
M form; Gibco Laboratories, Grand Island Biological Co., Grand Island, NY) or lymphoblastoid 
B cell lines transformed with Epstein-Barr virus (19). Incubation time for  the assays  ranged 
from 3-6 h; in antibody-blocking  assays, some effectors were harvested earlier than others in an 
attempt to achieve unblocked lysis in an optimum range (20-40%  specific lysis). Inhibition of 
cytotoxicity at the effector cell stage was performed by incubation of effectors with monoclonal 
antibodies for 15-20 rain before addition of SlCr-labeled target cells. 
Cell Separations and hnmunofluorescence.  To eliminate OKT3  +, OKT4  +, or OKT8  + cells by C'- 
mediated lysis, cells were incubated in a  1:10  '~ dilution of antibody ascites  (6 x  l06 cells/ml of 
antibody) for 30 min at 4°C, washed once, resuspended in a  1:10 dilution of normal rabbit 
serum (6 ×  106 cells/ml), incubated at 37°C for 40 rain, and washed once. The reactivities of BIDDISON,  RAO,  TALLE,  GOLDSTEIN,  AND  SHAW 
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Responder/  E/T§ 
Stimulator:~ 
Percent specific lysis of target cells* 
E2B  FB5B  FB5T  FBllB  FBllT  H9B  H9T  M4B  M4T  M14B 
FB6 anti-FB11  50:1  12  5  2  57  9  35  8  41  14  13 
(Anti-SB1)  17:1  6  0  1  55  5  26  8  27  10  5 
HLA antigens  --  --  --  SB1  SB1  SB1  SB1  SBI  SB1  -- 
recognized [[ 
S 11 anti-H9  50:1  3  3  0  43  3  20  4  22  6  1 
(Anti-SBl)  17:1  1  1  0  38  3  10  2  15  3  0 
HLA antigens  --  --  --  SB1  SBI  SB1  SB1  SBI  SB1  -- 
recognized 
W7 anti-H9  50:1  5  2  0  7  1  20  3  26  6  0 
(Anti-SB2)  17:1  1  -1  -1  3  1  14  0  15  4  0 
HLA antigens  .....  SB2  SB2  SB2  SB2  -- 
recognized 
H9 anti-W7  50:1  8  28  1  3  I  0  0  1  0  15 
(Anti-SB4)  17:1  2  13  0  1  0  -1  -1  -1  0  6 
HLA antigens  --  SB4  SB4  ......  SB4 
recognized 
* Target cells were either Epstein-Barr virus-transformed B cell lines (B) or PHA-stimulated PBL (T). 
:~ Cytotoxic effector cells were generated in tertiary cultures as described in Materials and Methods. 
§ Effector/target ratio. 
11 Specificities listed are the only known HLA specificities shared between stimulator and target but absent 
from responder cells. HLA typing results are as follows: E2: A3, B7, DR1, 4, SB3, MB1, 3; FB5: A25, 33, 
BI5,  17, C3, DR4, 5, SB4, 4; FB6: A25, 33, B15, 40, C3, DR4, 4, SB4; FBI 1: A25, 31, B15, 40, C3, DR4, 
4, SBI; H9: AI, 2, B7, 8, DR2, 3, SB1, 2;  M4: A1, 29, B13, 37, C2, 6, DR7, SB1, 2;  M14: A1, 2, B7, 8, 
DR2, 3, SB3, 4; SII: A1, 2, B7, 8, DR2, 3, SB2, 5; and W7: A1, 2, B7, 8, DR2, 3, SB1, 4. 
cell populations with monoclonal antibodies  (at  saturating concentrations)  were analyzed by 
indirect  immunofluorescence using a  fluorescence-activated cell sorter  (FAGS IV;  B-D FAGS 
Systems, Becton, Dickinson  &  Co., Sunnyvale, CA), as previously described (30). Cell surface 
antibody was  detected with  a  fluorescein-conjugated  F(ab')2  preparation  of goat  anti-mouse 
IgG (heavy and light chain specific, N. L. Gappel Laboratories, Cochranville, PA). 
Results 
Specificity of CTL.  The SB-specific CTL were generated in MLC between donors' 
cells  that  were  matched  for  HLA-A,  -B,  -C,  -D,  -DR,  MB,  and  MT  but  were 
mismatched for SB.  The specificity of these responses is well characterized  because 
these  combinations  of responder  and  stimulator  cells  are  those  originally  used  to 
define the SB antigens (19,  29). The specificity of some of these effectors is illustrated 
in Table I. The effectors lyse only B cells but not T  lymphoblasts autologous to the B 
cells  (e.g.,  57%  vs.  9%,  43%  vs.  3%).  Lysis  is  observed  on  targets  that  share  the 
sensitizing SB antigen with the stimulator cell but no other defined HLA-A, -B, -DR., 
MB,  or MT antigens.  In addition  to SB-specific CTL, HLA-A2-specific CTL were 
generated in MLC by stimulation of donors' cells that are disparate at HLA-A2 but 
no other HLA-A or -B antigen. 
Antibody plus C' Elimination of CTL.  CTL generated  against  SB 1,  SB2,  SB3,  and 
SB4  were  treated  with  OKT3,  OKT4,  or  OKT8  plus  C'  immediately before  the 1068  OKT4  ÷  SB-SPECIFIC  CYTOTOXIC  T  LYMPHOCYTES 
50 
40 
~,  30 
(J 
it. 
o-  20  (~ 
10 
0.  5:  :1  40:1 
B 
.625:1  2.5:1  10:1  40:1 
EFFECTOR:TARGET 
C 
0.625:1  2.5:1  10:1  40:1 
FIc.  1.  Treatment of SB-specific  CTL with antibody and C'. CTL specific  for SB antigens were 
generated  by stimulating responder PBL with irradiated  stimulator PBL in culture as follows: panel 
A, anti-SB2 (W7 anti-It9 assayed on M4 B cell targets);  panel B, anti-SB4 (H9 anti-W7 assayed  on 
FB5  B cell  targets);  and panel  C, anti-SB1  (Sll  anti-H9  assayed  on  FBll  B cell  targets),  ttLA 
typing  results  for  all  donors  in  these  panels  are  given  in  footnote(l~)  to  Table  I.  CTL  effector 
populations were either untreated  (0) or treated  with C' alone (C)), OKT3 +  C' (A), OKT4 +  C' 
([]),  OKT8 +  C' (I), or OKT4 +  OKT8 +  C' (&), before  addition to target  cells. 
TABLE  II 
Reactivity of SB-specific and HLA-A2-speclfic  CTL with OKT Antibodies 
Antigen  Responder/stimulator  *  Target cell 
recognized 
Ceil surface  Relative Iytic 
Percent inhibition b';,' antibody 
phenotype  activity 
OKT4A/ 
OKT4  +  OKT8  +  OKT4  OKT8  ~c  OKT8§  OKT3§  4B II 
%  '2/ 
Stt[  FB6 anti-Fgl I  HgB  NDg  ND  <1  >99  14  70  64 
S11 anti  H9  FB11B  ND  ND  <2  >98  9  76  68 
SB2  W7 anti-H9  M4B  89  2  < 1  >99  6  59  25 
F2 anti-B 17  M4B  ND  ND  ND  ND  17  69  13 
SB3  W7 anti-M 14  M 19B  95  7  <3  >97  -3  70  66 
SB4  H9 antiW7  FB5B  73  14  <1  >99  24  83  75 
FBI I anti-FB6  W7B  92  7  <:3  >99  14  68  45 
HLA-A2  Primary FR4/W5  QIT  61  23  >83  < 17  63  85  -27 
Secondary  FR4/W5  QIT  57  43  :>86  <14  48  80  9 
* SB specific  CT1, were generated in secondary and tertiary M1,C 
~r Percent  lelativc lyric activity remaining after treatment with OKT4 plus  C' (OKT4  i ot OKT8 plus  C' (OKT8  I 
§ Calculated as 100 -  (percent specific  lysis in  the plcsence of antibody  [5 #g/mll/percem specific  ]ysis in the absence of antibtJdy X  I(10) 
II CalcuLated as percent inhibition  by OKT4A (5 gg/ml) +  percent inhibition by OKT4B (5 gg/ml) /  2 
¶ Not deter mined 
addition  to  appropriate  51Cr-labeled  B  cell  targets.  Results  of titrating  treated  and 
control  untreated  CTL  populations  specific  for  SB 1,  SB2,  and  SB4  are  illustrated  in 
Fig.  1.  All  SB-specific  CTL  activity  could  be  eliminated  by  treatment  with  C'  plus 
OKT3,  OKT4,  or  mixed  OKT4  and  OKTS,  but  not  by  treatment  with  C'  alone  or 
with OKT8  plus C'. When  OKT4-  cells were rare in a  CTL  population,  treatment  of 
these  populations  with  OKT4  and  C'  resulted  in  low  cell  yields,  and,  consequently, 
not  all  of  these  populations  could  be  tested  at  the  highest  effector-to-target  ratio 
(40:1).  Comparisons  of overall  lytic  activity  (Table  II),  which  take  into  account  both 
cell  yield  and  cytotoxic  activity,  indicate  that  <:3%  of  the  recovered  activity  was 
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Fro.  2.  Treatment  of HLA-A2-specific  CTL  with  antibody  and  C'.  Primary  (panel  A)  and 
secondary (panel  B) HLA-A2-specific CTL were prepared by sensitization of FR4 PBL (A1, 1, B8, 
8, DR1, 4, SB4) against W5 PBL (A2, B8, DR3, SB2, 4) and assayed on PHA-stimulated targets 
from donor Q1  (A2, 3,  B7,  44,  C4,  DR1,  7,  SB4). CTL effector populations were treated with 
antibodies and C', as described in the legend to Fig.  1. 
treated  population  (Table  II).  FACS  analyses  before  treatment  with  monoclonal 
antibodies and C' indicated that 73-95% of all cells in the SB-specific CTL populations 
were OKT4  +, whereas only 2-14% of these cells were OKT8  + (Table II). 
The  elimination  of SB-specific  cytotoxicity  by  OKT4  but  not  OKT8  plus  C' 
contrasted with results previously reported for primary allogeneic CTL responses (14). 
To assure that these differences were not due to enrichment of or selection for different 
subpopulations of cells in secondary (and tertiary) responses, HLA-A2-specific CTL 
were  analyzed  both  in  primary  and  secondary  responses  (Fig.  2  and  Table  II). 
Although the SB-specific cultures contained predominantly OKT4  + cells, the second- 
ary anti-HLA-A2 population contained approximately equal numbers ofOKT4 + and 
OKT8  + cells. Removal of the OKT8  + cells but not the OKT4  + cells eliminated the 
HLA-A2-specific cytotoxicity generated in both primary and secondary cultures. 
Inhibition of Cytotoxicity by Monoclonal Antibodies.  Studies of antibody blocking (in the 
absence of complement) were undertaken to determine whether the OKT8 molecule 
plays a  functional  role in  both class I-specifc and class II-specific cytotoxicity and 
whether the OKT4 molecule plays a functional role in cytotoxicity of either specificity. 
SB-specific and HLA-A2-specifc cytotoxicity was analyzed in the presence of mono- 
clonal  antibody  against  OKT8  and  each  of a  series  of monoclonal  antibodies  to 
unique noncompeting epitopes on the OKT4 molecule (OKT4, 4A, 4B, 4C, and 4D). 2 
The OKT3 antibody, which is known to inhibit  many T  cell functions  (16,  31-33), 
was included  as a  positive control.  Two negative controls consisted  of OKT1  (25), 
which  reacts  with  all  peripheral  T  cells,  and  OKT9  (28),  which  reacts  with  the 
transferrin receptor. Detailed blocking data are shown for six representative effectors 
(Fig.  3);  a  simplified summary of these  six effectors and  others  that  were tested  is 
provided in Table II. CTL specific for SB1  (Fig. 3, panel A) were strongly inhibited 
by OKT3 but not by OKT1, OKT8, or OKT9. OKT4A and 4B partially inhibited 
Rao, P.  E.,  M. A. Talle, P.  Kung, and G.  Goldstein. Five epitopes of a  differentiation antigen on 
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Fie.  3.  Inhibition ofcytotoxicity by monoclonal antibodies. CTL against  SB antigens and tILA- 
A2 were prepared  as follows:  anti-SB1  (panel A, FB6 anti-FBll  assayed  on H9 B cells);  anti-SB3 
(panel B, W7 anti-Ml4 assayed on MI9 B cells);  anti-SB4 (panel  C, H9 anti-W7 assayed  on FB5 B 
cells);  anti-SB2  (panel  D, F2 anti-UB17  assayed  on M4 B cells);  anti-SB2  (panel E, W7 anti-H9 
assayed  on  M4 B cells);  and anti-HLA-A2  (panel F, FR4 anti-W5  assayed  on QI  T  cells).  CTL 
activity was assayed  in the absence  (Q)  or in the presence  of monoclonal antibodies OKT1  (~), 
OKT3 (O), OKT4 (F3), T4A (O), T4B  (O), T4C  i),  T4D  (A), OKTSA (A), and OKT9 (X).  All 
antibody-blocking assays were performed  with an effector-to-target  ratio of 40: 1. HLA typing results 
for donors  not previously  given in the legends to Figs.  1 and 2 and Table I are as follows:  F2: A1, 
2, B7, 8, DR2, 4, SB4, 5; M14:  A1, 2, B7, 8, DR2, 3, SB3, 4; M19:  A3, 11, B35, 51, C4, SB3, 4; and 
UB17:  A1, 2, B7, 8, DR2, 4, SB2, 4. 
SBl-specific  cytotoxicity,  with  a  plateau  of  inhibition  observed  over  a  fivefold 
concentration  of antibody  between  5  and  25 ~tg/ml.  OKT4,  4C,  and 4D  were unable 
to  signifiicantly  inhibit  SBl-specific  cytotoxicity.  Similar  results  were  obtained  for  a 
different  SBl-specific  CTL  population  (Table  II),  an  SB3-specific  CTL  population 
(Fig.  3, panel  B;  and Table  II),  and two different  SB4-specific  CTL  populations  (Fig. 
3, panel  C;  and Table  II). 
In contrast,  two  different  anti-SB2-specific  CTL  populations  (Fig.  3, panels  D  and 
E;  and Table  II)  were strongly  inhibited by OKT3  but were not well blocked  by any 
of the  OKT4  antibodies.  The  inability  of OKT4A  and 4B  to  block  anti-SB2-specific 
killing is not due to an absence  of OKT4A  and 4B  on these cells because  >95%  of the BIDDISON,  RAO,  TALLE,  GOLDSTEIN, AND  SHAW  1071 
cells  in  the  CTL population  in  panel  E  bound  OKT4,  4A,  and  4B  antibodies  by 
FACS  analysis  (data  not  shown).  The  lack  of inhibition  with  OKT4A  and  4B  is 
apparently a  function of the specificity of the CTL rather than of the genetics of the 
responder cell because the same responder cells (W7) that were sensitized against SB3 
(W7 anti-M14,  Fig. 3, panel B; and Table II) and against SB2  (W7 anti-H9; Fig. 3, 
panel E; and Table II) were differentially inhibited by OKT4A and 4B. 
HLA-A2-specific CTL (Fig. 3, panel F; and Table II) were not inhibited by any of 
the OKT4 antibodies, but were inhibited by OKT3 and OKT8. 
Discussion 
The results of the present studies demonstrate that in six SB-specific CTL popula- 
tions tested, many more cells express OKT4 antigens than OKT8 antigens, and >95% 
of the SB-specific cytotoxic activity is mediated by cells that are eliminated by OKT4 
plus complement but not by OKT8 plus complement. These data indicate that OKT4 
may be expressed on  SB-specific but  not  on  HLA-A2-specific CTL.  Although  it  is 
possible that the cells that mediate SB-specific killing express low levels of OKT8 and 
are therefore resistant  to treatment with OKT8 and complement, flow microfluoro- 
metric analysis of cells after treatment with antibody and complement has provided 
no evidence for this hypothesis (data not shown). Because some CTL express detectable 
levels of OKT8  (but not OKT4)  and other CTL express detectable levels of OKT4 
(hut not OKTS), expression of these differentiation antigens does not correlate with 
function  but  may correlate with  specificity. This possibility is  strengthened  by the 
combined results of these studies and those of Krensky et al. (17), which indicate that 
CTL lines  specific for DRw6  were  OKT4+8  -,  but  control  populations  specific  for 
HLA-A2 or -B7 were OKT4-8  ÷. Thus, CTL specific for products of two distinct  Ia- 
like genes, SB and DR, express OKT4 but not OKTS. Conversely, CTL specific for 
class I antigens express OKT8 but not OKT4. It would appear that the OKT4 marker 
may be expressed on most T  cells that recognize allogeneic Ia antigens or self Ia plus 
foreign antigens; these OKT4  + cells do not appear to be functionally homogeneous in 
that they can act both as helper/inducer and cytotoxic cells. 
Data from at least two laboratories suggest that OKT4 may be expressed on CTL 
clones that apparently are not specific for class II antigens.  Moretta et al.  (34)  have 
demonstrated  that  CTL  clones  derived  from  MLC  can  have  the  phenotypes 
OKT4-8-, OKT4+8  -, or OKT4-8  +. The specificity of these effectors was not defined, 
but because all of the OKT4+8  -  CTL clones produced >37% lysis of PHA-induced 
lymphoblasts, they presumably were not specific for class II antigens.  Pawalec et al. 
(35)  have also observed OKT4+8  -  clones that strongly lysed peripheral blood mono- 
nuclear cells. It is uncertain whether the expression of T  cell differentiation antigens 
on long-term cultured cells maintained with TCGF accurately reflects normal differ- 
entiation or whether unusual events predominate, such as selection for rare cell types 
or expression of aberrant  phenotypes. Thus,  the OKT4 marker may be present  on 
most if not all class II-specific CTL as well as some long-term CTL clones with  no 
apparent class II specificity. 
Studies  of  CTL  inhibition  by  monoclonal  antibodies  suggest  that  the  OKT4 
molecule is not only expressed on SB-specific CTL, but it may be involved in CTL- 
target cell interactions  (recognition and lethal hit).  The OKT4A and 4B antibodies 
were able to inhibit  the lysis of five SB-specific CTL populations by 45-75%. These 1072  OKT4  ÷ SB-SPECIFIC CYTOTOXIC T  LYMPHOCYTES 
results  indicate  that  the  OKT4A  and  4B  antibodies  interfere  with  effector T  cell 
function  because  these  antibodies  cannot  bind  to  the  B  cell  targets.  The  OKT4 
molecule apparently is not an essential component of the lytic machinery because it 
is not present on HLA-A2-specific CTL. The simplest hypothesis is that  the OKT4 
molecule is involved in antigen recognition by SB-specific CTL because its presence 
and function correlate with antigen specificity (i.e., class I vs. class II). This hypothesis 
is supported  by two findings:  (a)  antibodies  against  a  molecule  (Leu-3)  apparently 
identical  to  OKT4  inhibited  proliferation  of Leu-3  +  cells  in  MLC  (36);  and  (b) 
preliminary results indicate that OKT4A and 4B can block SB-specific proliferative 
responses (unpublished observations). Interference with antigen recognition could be 
the  mechanism  by which  antibody  is  able to  inhibit  both  T  cell  proliferation  and 
cytotoxicity. 
Three  elements  of complexity  need  to  be  considered  in  the  data  on  antibody- 
mediated inhibition.  First, blocking by OKT4A and 4B is not complete but reaches 
a plateau of inhibition over a fivefold range of antibody concentrations. These results 
could reflect the fact that the antibodies are not binding directly to the T  cell antigen 
recognition unit, but rather that they bind to epitopes near the recognition unit and 
cause partial steric inhibition. Alternatively, there may be clonal heterogeneity of SB- 
specific CTL, such that only a portion of the CTL clones are susceptible to inhibition. 
A precedent for such clonal heterogeneity has been provided by MacDonald et al. in 
their studies of inhibition  of CTL clones  by anti-Lyt-2 antibodies  (10).  The second 
complexity is that OKT4, 4C, and 4D bind to the same molecule as OKT4A and 4B, z 
but are unable to inhibit CTL activity. These results could indicate that the OKT4, 
4C, and 4D antibodies have a lower affinity than 4A and 4B for the OKT4 molecule 
or that the OKT4, 4C, and 4D epitopes are located at some greater distance from the 
antigen-recognition site on the CTL. The third complexity, lack of inhibition of SB2- 
specific  cytotoxicity  by  OKT4A  and  4B  antibodies,  is  open  to  several  different 
explanations.  The  most  provocative  hypothesis  to  explain  this  apparent  antigen 
specificity of inhibition is that the OKT4 antibodies bind to a site on the T  cell that 
is in close proximity to the binding site of the T  cell antigen-specific receptors that 
recognize some but not other Ia antigens.  However, preliminary results of antibody 
inhibition  of proliferation  indicate  that  SB2-specific  proliferation,  like  other  SB- 
specific proliferation, is partially inhibitable by OKT4A and 4B (unpublished obser- 
vations). These results indicate that there may not be anything fundamentally unique 
about  SB2-specific T  cell  recognition.  Instead,  postulates  such  as  higher  affinity of 
SB2-specific effectors or unique geometry of SB2-specific CTL recognition are ad hoc 
explanations for the failure to block SB2-specific CTL. 
Despite the foregoing complexities, the results presented in this report are consistent 
with the basic concept that the OKT4 molecule may be involved in T  cell recognition 
of class  II  HLA  antigens.  Data  from  other  studies  also  suggest  that  the  OKT4 
molecule is functionally involved in T  cell-Ia antigen interactions. The findings that 
OKT4+8  -  cells are located adjacent to Ia  + cells in lymphohematopoietic organs and 
gut mucosa (37,  38)  indicates that OKT4  + cells possess a cell surface mechanism that 
enables them to preferentially associate with la  + cells.  Perhaps the OKT4 molecule 
provides  a  low  affinity  recognition  mechanism  by which  these  cells  home  to  and 
survey the  limited  population  of Ia  + cells  in  the  body.  Such  a  homing or  focusing 
mechanism would facilitate reactivity of these cells with Ia  + antigen-presenting cells. BIDDISON, RAO, TALLE, GOLDSTEIN, AND SHAW  1073 
As  a  stimulus  for discussion,  we  propose  two  possible  molecular  models  for  the 
interaction  of OKT4  +  T  cells  with  Ia antigens  (Fig.  4):  one  in  which  the  OKT4 
molecule is  the T  cell receptor for class II antigens  and another in which  it acts in 
concert  with  the  T  cell  receptor.  In  both  models,  we  propose  that  an  invariant 
structure  on  the  OKT4  molecule  interacts  with  an  invariant  structure  on  the  Ia 
molecule. Such an interaction of nonpolymorphic structures, which  is characteristic 
of most receptor-ligand interactions  outside  the  immune system, would  be efficient 
from an evolutionary and genetic point of view because it would assure satisfactory 
interaction of class II-specific T  cells with autologous Ia  + cells in individuals of any 
genotype. It is possible that the antigen-specific T  cell receptor and this invariant Ia 
receptor are on the same polypeptide chain  (the OKT4 molecule)  (Fig. 4, panel A). 
Alternatively,  the  OKT4  molecule  and  the  T  cell  receptor  could  be  distinct  cell 
surface structures  but would be intimately associated during Ia antigen  recognition 
(Fig. 4, panel B). Structural studies of the heterogeneity of OKT4 will be required to 
differentiate between these two possibilities. 
Summary 
A  recently  described  HLA gene,  SB,  which  maps between  GLO and  HLA-DR, 
codes for Ia-like molecules that are similar to but distinct  from HLA-DR molecules. 
Cytotoxic T  lymphocytes (CTL) specific for SB 1, SB2, SB3, and SB4 were compared 
with  HLA-A2-specific CTL  with  respect  to  their  surface  expression  of the  T  cell 
differentiation antigens OKT3, OKT4, and OKT8. All CTL activity was eliminated 
by treatment  with  OKT3  and  C'.  The  SB-specific cytotoxicity was  eliminated  by 
OKT4 plus C' but not  by OKT8 plus C'. In contrast,  HLA-A2-specific killing was 
completely susceptible to treatment with OKT8 plus C' but not with OKT4 plus C'. 
Cytotoxicity  was  analyzed  in  the  presence  of OKT8  and  a  series  of monoclonal 
antibodies (OKT4A, 4B, 4C, and 4D) that react with distinct epitopes on the OKT4 
molecule. SB 1-, SB3-, and SB4-specific CTL were partially inhibited by OKT4A and 
4B (45-75%), whereas HLA-A2-specific CTL were partially inhibited by OKT8 (48- 
63%) but not by OKT4. SB2-specific CTL were not inhibited (<26%) by OKT8 or by 
any of the  OKT4-related  antibodies.  These results suggest  that  the OKT4 marker 
may be expressed on most T  cells that recognize allogeneic Ia or self Ia plus foreign 
antigens;  OKT4  + cells do not appear to be functionally homogeneous in  that  they 
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can  act  both  as  helper/inducer and  cytotoxic  cells.  Models  are  proposed  for  the 
functional involvement of the OKT4 molecule in T  cell-Ia antigen interactions. 
Note added in proof" Meuer et al. (Proc.  Natl.  Acad.  Sci.  U.  S.  A.  79:4395) and Ball and 
Stastny (Immunogenetics, in press) have recently described class II-specific OKT4+CTL. 
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